Meta‐Analysis: Redefining Liver Disease Risk in Heterozygous Alpha‐1 Antitrypsin Deficiency
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70814 ↗At a glance
Metaanalyse in Alimentary Pharmacology & Therapeutics, 2026. Written by Adam M Syanda and 8 co-authors. Institution: Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK. Major MEDLINE topics: alpha 1-Antitrypsin Deficiency, Liver Diseases, alpha 1-Antitrypsin. Cited 1 times so far (Crossref); 52 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
Heterozygous SERPINA1 genotypes (MZ, SZ) have historically been regarded as carrier states with limited liver relevance. Emerging evidence suggests increased liver injury, but the magnitude of risk remains uncertain. We synthesized evidence on heterozygous SERPINA1 liver phenotypes to quantify this risk.
Methods
We performed a systematic review of bibliographic databases from inception to 21 October 2025 for studies reporting liver outcomes in MZ or SZ genotypes. Outcomes were grouped into metabolic comorbidities, biochemical markers, and clinical liver disease. Random‐effects meta‐analyses pooled mean differences (MDs) and odds ratios (ORs); risk of bias was assessed with established tools (PROSPERO CRD420251165586).
Results
Twenty‐six studies including 27,933 heterozygotes and 547,961 controls met inclusion criteria. BMI (MD −0.09 [−0.20–0.02]) and steatosis risk (OR 1.09 [0.74–1.60]) were comparable between groups. Heterozygotes had modestly higher liver enzymes (ALT MD 1.03 [0.41–1.66]; AST MD 0.68 [0.51–0.85]; ALP MD 2.58 [1.58–3.58]) and higher odds of abnormal ALT (OR 1.18 [1.11–1.25]), AST (OR 1.16 [1.07–1.26]), and ALP (OR 1.41 [1.18–1.68]). They had significantly increased odds of fibrosis (OR 2.14 [1.52–3.02]), cirrhosis (OR 2.24 [1.73–2.91]), and liver transplantation (OR 2.28 [1.45–3.59]).
Conclusions
Heterozygous SERPINA1 genotypes are bona fide liver risk states, with effect sizes comparable to established genetic and environmental determinants. MZ / SZ heterozygosity should be recognized as moderate‐penetrance liver susceptibility genotypes in chronic liver disease risk assessment.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.
- Department of Population Health Sciences, School of Life Course and Population Sciences, King's College London, London, UK.
- Faculty of Medicine, Imperial College London, London, UK.
- Institute of Liver Studies, King's College London, London, UK.
ORCID profiles: Adam M Syanda
Cite
APA
Syanda, A. M., Georgantaki, D., Linn, R. T. T., Agbai, A., Tahir, H., Sakai, M., Thompson, R., Molokhia, M., & Rashid, S. T. (2026). Meta‐Analysis: Redefining Liver Disease Risk in Heterozygous Alpha‐1 Antitrypsin Deficiency. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70814
Vancouver
Syanda AM, Georgantaki D, Linn RTT, Agbai A, Tahir H, Sakai M, et al. Meta‐Analysis: Redefining Liver Disease Risk in Heterozygous Alpha‐1 Antitrypsin Deficiency. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70814
BibTeX
@article{Syanda2026,
author = {Syanda, Adam M and Georgantaki, Dimitra and Linn, Riona T T and Agbai, Amara and Tahir, Hassan and Sakai, Manako and Thompson, Richard and Molokhia, Mariam and Rashid, S Tamir},
title = {Meta‐Analysis: Redefining Liver Disease Risk in Heterozygous Alpha‐1 Antitrypsin Deficiency},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70814}
}
EUVIMED